NCT02138084View on ClinicalTrials.gov

Drug-drug Interaction (DDI) Rifabutin

PHASE1CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

May 14, 2014

Primary Completion Date

July 24, 2014

Study Completion Date

July 24, 2014

Conditions
Infection, Human Immunodeficiency Virus
Interventions
DRUG

BMS-663068

BMS-663068

DRUG

Rifabutin

Rifabutin

DRUG

Ritonavir

Ritonavir

Trial Locations (1)

78744

GSK Investigational Site, Austin

Sponsors

Lead Sponsor

ViiV Healthcare

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

ViiV Healthcare

INDUSTRY